Retraction: Endogenous urotensin II selectively modulates erectile function through eNOS (PLoS One (2012) 7:2 (e31019) DOI: 10.1371/journal.pone.0031019);Endogenous Urotensin II selectively modulates erectile function through eNOS

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  d'Emmanuele di Villa Bianca, Roberta ^a   Mitidieri, Emma ^a   Fusco, Ferdinando ^a   D'Aiuto, Elena ^b   Grieco, Paolo ^a   Novellino, Ettore ^a   Imbimbo, Ciro ^a   Mirone, Vincenzo ^a   Cirino, Giuseppe ^a   Sorrentino, Raffaella ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GELDANAMYCIN; MESSENGER RNA; NITRIC OXIDE; UROTENSIN II; WORTMANNIN;

ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CORPUS CAVERNOSUM; ENZYME ACTIVATION; FLUOROMETRY; HUMAN; HUMAN TISSUE; MALE TO FEMALE TRANSSEXUAL; PENIS ERECTION; PEPTIDE ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; QUANTITATIVE STUDY; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE DISTRIBUTION; VASODILATATION; WESTERN BLOTTING;

EQUUS ASINUS; TELEOSTEI;

EID: 84866496072     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0222415     Document Type: Erratum

References (38)

1. Douglas SA, Ashton DJ, Sauermelch CF, Coatney RW, Ohlstein DH, et al. (2000) Human urotensin-II is a potent vasoactive peptide: Pharmacological characterization in the rat, mouse, dog and primate. J Cardiovasc Pharmacol 36 (5 suppl 1): S163-166.
2. MacLean MR, Alexander D, Stirrat A, Gallagher M, Douglas SA, et al. (2000) Contractile responses to human urotensin-II in rat and human pulmonary arteries: Effect of endothelial factors and chronic hypoxia in the rat. Br J Pharmacol 130: 201-204.
3. Rossowski WJ, Cheng BL, Taylor JE, Datta R, Coy DH, (2002) Human urotensin II-induced aorta ring contractions are mediated by protein kinase. C, tyrosine kinases and Rho-kinase: Inhibition by somatostatin receptor antagonists. Eur J Pharmacol 438: 159-170.
4. Bottrill FE, Douglas SA, Hiley CR, White R, (2000) Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br J Pharmacol 130: 1865-1870.
5. Stirrat A, Gallagher M, Douglas SA, Ohlstein EH, Berry C, et al. (2001) Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol 280: H925-928.
6. Böhm F, Pernow J, (2002) Urotensin II evokes potent vasoconstriction in humans in vivo. Br J Pharmacol 135: 25-27.
7. Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, et al. (1999) Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401: 282-286.
8. Chen YH, Yandle TG, Richards AM, Palmer SC, (2009) Urotensin II immunoreactivity in the human circulation: evidence for widespread tissue release. Clin Chem 55: 2040-2048.
9. Maguire JJ, Kuc RE, Davenport AP, (2000) Orphan-receptor ligand human urotensin II: Receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol 131: 441-446.
10. Zhu YC, Zhu YZ, Moore PK, (2006) The role of urotensin II in cardiovascular and renal physiology and diseases. Br J Pharmacol 148: 884-901.
11. Russell FD, (2004) Emerging roles of urotensin-II in cardiovascular disease. Pharmacol Ther 103: 223-243.
12. d'Emmanuele di Villa Bianca R, Cirino G, Mitidieri E, Coletta C, Grassia G, et al. (2010) Urotensin II: a novel target in human corpus cavernosum. J Sex Med 7: 1778-1786.
13. Ignarro LJ, Bush PA, Buga GM, Wood KS, Fukuto JM, et al. (1990) Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun 170: 843-850.
14. Burnett AL, Lowenstein CJ, Bredt DS, Chang TS, Snyder SH, (1992) Nitric oxide: a physiologic mediator of penile erection. Science 257: 401-403.
15. Alderton WK, Cooper CE, Knowles RG, (2001) Nitric oxide synthases: structure, function and inhibition. Biochem J 357: 593-615.
16. Nathan C, Xie QW, (1994) Nitric oxide synthases: roles, tolls, and controls. Cell 78: 915-918.
17. Busse R, Mülsch A, (1990) Calcium-dependent nitric oxide synthesis in endothelial cytosol is mediated by calmodulin. FEBS Lett 265: 133-136.
18. Garc'i{dotless}a-Cardena G, Fan R, Shah V, Sorrentino R, Cirino G, et al. (1998) Dynamic activation of dent activation of the endothelial nitric oxide synthase in response to endothelial nitric oxide synthase by Hsp90. Nature 292: 821-824.
19. Russell KS, Haynes MP, Caulin-Glaser T, Rosneck J, Sessa WC, et al. (2000) Estrogen stimulates heat shock protein 90 binding to endothelial nitric oxide synthase in human vascular endothelial cells. Effects on calcium sensitivity and NO release. J Biol Chem 275: 5026-5030.
20. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, et al. (1999) Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399: 597-601.
21. Michel T, Li GK, Busconi L, (1993) Phosphorylation and subcellular translocation of endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 90: 6252-6256.
22. Hurt KJ, Musicki B, Palese MA, Crone JC, Becker RE, et al. (2002) Akt-dependent phosphorylation of endothelial nitric oxide synthase mediated penile erection. Proc Natl Acad Sci U S A 99: 4061-4066.
23. d'Emmanuele di Villa Bianca R, Sorrentino R, Sorrentino R, Imbimbo C, Palmieri A, et al. (2006) Sphingosine 1-phosphate induces endothelial nitric-oxide synthase activation through phosphorylation in human corpus cavernosum. J Pharmacol Exp Ther 316: 703-708.
24. Takahashia K, Totsuneb K, Murakamib O, Shibaharaa S, (2001) Expression of urotensin II and urotensin II receptor mRNAs in various human tumor cell lines and secretion of urotensin II-like immunoreactivity by SW-13 adrenocortical carcinoma cells. Peptides 22: 1175-1179.
25. Burnett AL, (2004) Novel nitric oxide signaling mechanisms regulate the erectile response. Int J Impot Res 16 (Suppl 1): S15-19.
26. Burnett AL, Lowenstein CJ, Bredt DS, Chang TS, Snyder SH, (1992) Nitric oxide: a physiologic mediator of penile erection. Science 257: 401-403.
27. Toda N, Ayajiki K, Okamura T, (2005) Nitric oxide and penile erectile function. Pharmacol Ther 106: 233-266.
28. Ignarro LJ, Bush PA, Buga GM, Wood KS, Fukuto JM, Rajfer J, (1990) Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun 170: 843-850.
29. Burnett AL, Tillman SL, Chang TS, Epstein JI, Lowenstein CJ, et al. (1993) Immunohistochemical localization of nitric oxide synthase in the autonomic innervation of the human penis. J Urol 150: 73-76.
30. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, et al. (1999) Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399: 601-605.
31. Gallis B, Corthals GL, Goodlett DR, Ueba H, Kim F, et al. (1999) Identification of flow-dependent endothelial nitric-oxide synthase phosphorylation sites by mass spectrometry and regulation of posphorylation and nitric oxide production by the phosphatidylinositol 3-kinase inhibitor LY294002. Biol Chem 274: 30101-30108.
32. Boo YC, Kim HJ, Song H, Fulton D, Sessa W, et al. (2006) Coordinated regulation of endothelial nitric oxide synthase activity by phosphorylation and subcellular localization. Free Radic Biol Med 41: 144-153.
33. Fulton D, Gratton JP, Sessa WC, (2001) Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough? J Pharmacol Exp Ther 299: 818-824.
34. Gratton JP, Fontana J, O'Connor DS, Garcia-Cardena G, McCabe TJ, et al. (2000) Reconstitution of an endothelial nitric-oxide synthase (eNOS), hsp90, and caveolin-1 complex in vitro. Evidence that hsp90 facilitates calmodulin stimulated displacement of eNOS from caveolin-1. J Biol Chem 275: 22268-22272.
35. McMahon CN, Smith CJ, Shabsigh R, (2006) Treating erectile dysfunction when PDE5 inhibitors fail. BMJ 332: 589-592.
36. Grieco P, Carotenuto A, Campiglia P, Zampelli E, Patacchini R, et al. (2000) A new, potent urotensin II receptor peptide agonist containing a Pen residue at the disulfide bridge. J Med Chem 45: 4391-4394.
37. Mirone V, Sorrentino R, d'Emmanuele di Villa Bianca R, Imbimbo C, Palmieri A, et al. (2000) A standardized procedure for using human corpus cavernosum strips to evaluate drug activity. J Pharmacol Toxicol Methods 44: 477-482.
38. Misko TP, Schilling RJ, Salvemini D, Mooore WM, Currie MG, (1993) A fluorometric assay for the measurement of nitrite in biological samples. Analytical Biochemestry 214: 11-16.